A5062893255- Vaccine Coverage and Hesitancy
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Urinary Tract Infections Management
- Herpesvirus Infections and Treatments
- Antifungal resistance and susceptibility
- Antibiotic Use and Resistance
- COVID-19 and healthcare impacts
- Biochemical Analysis and Sensing Techniques
- Poxvirus research and outbreaks
- Fungal Infections and Studies
- Advanced Chemical Sensor Technologies
- Antibiotics Pharmacokinetics and Efficacy
- Olfactory and Sensory Function Studies
- Bartonella species infections research
- Pediatric Urology and Nephrology Studies
- Nosocomial Infections in ICU
- Vector-borne infectious diseases
- Blood properties and coagulation
- Acute Myocardial Infarction Research
- Long-Term Effects of COVID-19
- Hepatitis Viruses Studies and Epidemiology
- Insect and Pesticide Research
- Urinary Bladder and Prostate Research
- Bacillus and Francisella bacterial research
Tel Aviv Sourasky Medical Center
2015-2024
Tel Aviv University
2016-2024
Hebrew University of Jerusalem
2022
Israel Ministry of Health
2022
Cardiovascular Research Center
2016
<h3>Importance</h3> Administration of a BNT162b2 booster dose (Pfizer-BioNTech) to fully vaccinated individuals aged 60 years and older was significantly associated with lower risk SARS-CoV-2 infection severe illness. Data are lacking on the effectiveness doses for younger health care workers. <h3>Objective</h3> To estimate association infections among workers who were previously 2-dose series BNT162b2. <h3>Design, Setting, Participants</h3> This prospective cohort study conducted at...
Abstract In this cohort of 42 patients with mild COVID19 we found a unique clinical feature acute anosmia and dysgeusia in more than third patients. Median onset these features was 3.3 days after illness (range 0-7) rapid recovery most Article Summary Line Anosmia appeared early our SARS-CoV-2 infection were short-lived
Waning immunity and an increased incidence of coronavirus disease 2019 (COVID-19) during the Omicron outbreak led Israeli Ministry Health to recommend a fourth vaccine dose for high-risk individuals. In this study, we assessed its effect hospitalized patients with severe breakthrough COVID-19.In multicenter cohort study adults COVID-19 in Israel, from 15 31 January 2022, cases were divided according number vaccinations received. Poor outcome was defined as mechanical ventilation or...
High values of Red Blood Cell Distribution Width (RDW) have been associated with adverse outcome in various clinical settings. The mechanism behind this association is not clear. Metabolic Syndrome (MetS) a chronic inflammatory disorder that increases the risk for cardiovascular disease and death. aim our study was to evaluate between high RDW MetS relatively large cohort patients.A 3,529 consecutive patients undergoing coronary angiography used MetS. assessed by using logistic regression....
The urinary tract is considered an uncommon source of Candida bloodstream infection (CBSI). We aimed to determine the CBSI in hospitalized patients, and compare clinical microbiological features originating (U-CBSI) non-urinary (NU-CBSI). Of 134 patients with CBSI, 28 (20.8%) met criteria for U-CBSI, 34 (25.3%) had vascular catheter-related 21 (15.6%) a gastrointestinal origin. Compared NU-CBSI U-CBSI were older higher rates dementia. Bladder catheterization retention insertion ureteral...
To determine clinical outcomes associated with aminoglycosides versus other antimicrobial agents as empirical treatment of hospitalized patients pyelonephritis.An institutional programme promoting pyelonephritis was implemented in 2016. We reviewed the hospital records from January 2017 to April 2019. The primary outcome death within 30 days index culture. Initial aminoglycoside-based regimens compared non-aminoglycoside antibiotics. Propensity score matching performed adjust for...
Abstract Importance Waning immunity against COVID-19 in parallel with an increased incidence during the Omicron outbreak led Israeli Ministry of Health to recommend a second booster dose BNT162b2 (Pfizer) high-risk individuals. Israel was first country this, allowing evaluation added protection fourth vaccine hospitalized patients severe diseases. Objective To assess effect for severe/critical breakthrough COVID-19. Design A cohort study adults from 01/15/2022–01/31/2022. Settings...
Abstract Background Early reports described an increased risk of herpes zoster following receipt mRNA-based COVID-19 vaccines. The objective was to assess whether vaccine is associated with varicella-zoster virus–induced neurologic disease (VZV-ND). Methods This multicenter retrospective case-control study a test-negative design conducted at 12 hospitals in Israel. We included all patients admitted VZV-ND between January 2020 and December 2021 matched controls negative polymerase chain...
Covid-19 disease is implicated in increased mortality among immunocompromised patients. The JAK inhibitor, baricitinib (bar), or the IL-6 tocilizumab (toc), demonstrated a survival benefit patients with severe disease.However, evidence supporting their use scarce.We aimed to assess clinical outcomes of bar/toc treatment A multi-center registry consecutive hospitalized due during Omicron variant dominance period. After excluding who did not require high oxygen supply, treated were compared by...
The varicella-zoster virus causes infections that are often mild but can cause substantial morbidity and mortality in otherwise healthy children. We examined trends varicella-related hospitalisations before after the implementation of a national two-dose varicella vaccination programme Israel September 2008.This retrospective chart review, performed at three tertiary care paediatric hospitals greater Tel Aviv, compared data from 2004 to 2008 2009 2012, was launched. It included all children...
Previous studies investigating the prognostic value of HbA1c in patients undergoing coronary angiography reported a mixed pattern results. Therefore, we aimed to better define power among catheterized patients.Patients (n = 3,749) were divided into four groups according levels (<5, 5-6, 6-7 and >7%). Cox regression models assessed long-term mortality after adjusting for multiple covariates.Baseline clinical profiles differed groups, with higher prevalence comorbidities levels. Median...
Background Changing patterns of vaccine breakthrough can clarify effectiveness. Aim To compare infections during a SARS-CoV-2 Delta wave vs unvaccinated inpatients, and an earlier Alpha wave. Methods In observational multicentre cohort study in Israel, hospitalised COVID-19 patients were divided into three cohorts: Comirnaty-vaccinated (VD; Jun–Aug 2021) cases the (ND) (VA; Jan–Apr 2021). Primary outcome was death or ventilation. Results We included 343 VD, 162 ND 172 VA patients. VD more...
Antimicrobial resistance (AMR) has consistently been linked to antibiotic use. However, the roles of commonly prescribed non-antimicrobial drugs as drivers AMR may be under-appreciated. Here, we studied a cohort patients with community-acquired pyelonephritis and assessed association exposure at time hospital admission infection drug-resistant organisms (DRO). Associations identified on bivariate analyses were tested using treatment effects estimator that models both outcome probability....
Highly variable estimates of COVID-19-associated fungal diseases (IFDs) have been reported. We aimed to determine the incidence clinically important in hospitalized COVID-19 patients during first year pandemic. performed a multicenter survey IFDs among with 13 hospitals Israel between February 2020 and May 2021. pulmonary mold disease (PMD) invasive candidiasis (IC) were defined using ECMM/ISHAM EORTC/MSG criteria, respectively. Overall rates IC PMD critical 10.86 10.20 per 1000 admissions,...
ABSTRACT The reported estimates of bacterial co-infection in COVID-19 patients are highly variable. We aimed to determine the rates and risk factors develop a clinical prediction model support early decision-making on antibiotic use. This is retrospective cohort study conducted tertiary-level academic hospital Israel between March 2020 May 2022. All adult with severe who had blood or lower respiratory specimen sent for microbiological analyses within 48 h admission were included. primary...
Abstract Background & Objective : Covid-19 disease is implicated in increased mortality among immunocompromised patients. The JAK inhibitor, baricitinib (bar), or the IL-6 tocilizumab (toc), demonstrated a survival benefit patients with severe disease. However, evidence supporting their use scarce. We aimed to assess clinical outcomes of bar/toc treatment Design and Participants A multi-center registry consecutive hospitalized due during Omicron variant dominance period. After excluding...